Pulmatrix has released positive results from initial stage of Phase IB clinical trial of a bronchodilator therapy PUR0200 for patients with chronic obstructive pulmonary disease (COPD). The company said PUR0200 is the first small molecule ...
Pulmatrix has demonstrated iSPERSE capabilities for inhaled dry powder delivery of antibiotics, antibodies and other macromolecules. These preclinical data demonstrated the ability of iSPERSE formulations to deliver stable and ...
Pulmatrix has announced the results of a clinical study showing that an iCALM (inhaled cationic airway lining modulator therapy) attenuated allergen-induced bronchitis in susceptible asthmatic patients. The study concluded that iCALM is a ...
Pulmatrix, a developer of inhalable drug delivery platforms, has appointed Robert Clarke as the company's new chief executive officer (CEO). Previously, Clarke served as the company's chief scientific officer and vice president of ...